Multifunctional Vector for Delivery of Genome Editing Plasmid Targeting β-Catenin to Remodulate Cancer Cell Properties.

Accurate and efficient delivery of genome editing plasmids to targeted cells is of critical importance in genome editing. Herein, we prepared a multifunctional delivery vector with a combination of ligand-mediated selectivity and peptide-mediated transmembrane function to effectively deliver plasmids to targeted cancerous cells. In the delivery system, the clustered regularly interspaced short palindromic repeat-associated Cas9 nuclease (CRISPR-Cas9) plasmid is combined with protamine with membrane and nuclear translocating activities and co-precipitated with CaCO3, which is further decorated by AS1411-functionalized carboxymethyl chitosan and cell penetrating peptide (TAT)-functionalized carboxymethyl chitosan. The AS1411-mediated tumor cell/nuclear targeting and TAT-induced enhanced endocytosis result in obviously increased cellular uptake and nuclear transport. As a result, the CRISPR-Cas9 plasmid can be efficiently delivered to cancer cell nuclei to mediate genome editing, resulting in an efficacious knockout of CTNNB1 gene encoding β-catenin. More importantly, downregulation of β-catenin could effectively prevent its enrichment in nuclei and then significantly downregulate the expression of proteins, such as vimentin, Snail, MMP-2, MMP-9, CD44, Nanog, and Oct4 to prevent tumor progression and metastasis. The edited cancerous cells exhibit favorable remodulated properties including inhibited growth, suppressed migration and invasion, and reduced cancer stemness.

[1]  Xuenong Zhang,et al.  Nucleolin-Targeting AS1411-Aptamer-Modified Graft Polymeric Micelle with Dual pH/Redox Sensitivity Designed To Enhance Tumor Therapy through the Codelivery of Doxorubicin/TLR4 siRNA and Suppression of Invasion. , 2018, Molecular pharmaceutics.

[2]  John O Trent,et al.  Discovery and development of the G-rich oligonucleotide AS1411 as a novel treatment for cancer. , 2009, Experimental and molecular pathology.

[3]  G. Rettig,et al.  Knockdown of β-catenin with Dicer-Substrate siRNAs Reduces Liver Tumor Burden In vivo , 2013, Molecular therapy : the journal of the American Society of Gene Therapy.

[4]  K. Kalland,et al.  Small molecule promotes β-catenin citrullination and inhibits Wnt signaling in cancer. , 2018, Nature chemical biology.

[5]  Luigi Naldini,et al.  Gene therapy returns to centre stage , 2015, Nature.

[6]  A. Zimmer,et al.  Protamine-oligonucleotide-nanoparticles: Recent advances in drug delivery and drug targeting. , 2015, European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences.

[7]  Zhangyong Hong,et al.  Targeted Delivery of CRISPR/Cas9‐Mediated Cancer Gene Therapy via Liposome‐Templated Hydrogel Nanoparticles , 2017, Advanced functional materials.

[8]  J. Hwang,et al.  Cell-Penetrating Peptide-Patchy Deformable Polymeric Nanovehicles with Enhanced Cellular Uptake and Transdermal Delivery. , 2018, Biomacromolecules.

[9]  Fajr A. Aleisa,et al.  Endosomal Escape and Delivery of CRISPR/Cas9 Genome Editing Machinery Enabled by Nanoscale Zeolitic Imidazolate Framework. , 2018, Journal of the American Chemical Society.

[10]  Gang Bao,et al.  CRISPR/Cas9-Based Genome Editing for Disease Modeling and Therapy: Challenges and Opportunities for Nonviral Delivery. , 2017, Chemical reviews.

[11]  Dan Zhang,et al.  The role of β-catenin in the initiation and metastasis of TA2 mice spontaneous breast cancer , 2017, Journal of Cancer.

[12]  T. Aminabhavi,et al.  Targeted delivery of small interfering RNA to colon cancer cells using chitosan and PEGylated chitosan nanoparticles. , 2016, Carbohydrate polymers.

[13]  M. Stratton,et al.  The cancer genome , 2009, Nature.

[14]  Chao Wang,et al.  Self-assembled DNA nanoclews for the efficient delivery of CRISPR-Cas9 for genome editing. , 2015, Angewandte Chemie.

[15]  Zhen Gu,et al.  Macrophage-Specific in Vivo Gene Editing Using Cationic Lipid-Assisted Polymeric Nanoparticles. , 2018, ACS nano.

[16]  Yafeng Song,et al.  Down-regulation of lncRNA CASC2 promotes cell proliferation and metastasis of bladder cancer by activation of the Wnt/β-catenin signaling pathway , 2017, Oncotarget.

[17]  Jennifer A. Doudna,et al.  Enhanced proofreading governs CRISPR-Cas9 targeting accuracy , 2017, Nature.

[18]  Christian Veltkamp,et al.  Multiplexed pancreatic genome engineering and cancer induction by transfection-based CRISPR/Cas9 delivery in mice , 2016, Nature Communications.

[19]  F. Beltram,et al.  A novel chimeric cell-penetrating peptide with membrane-disruptive properties for efficient endosomal escape. , 2012, Journal of controlled release : official journal of the Controlled Release Society.

[20]  T. Ohtsuki,et al.  Enhanced intracellular peptide delivery by multivalent cell-penetrating peptide with bioreducible linkage. , 2017, Bioorganic & medicinal chemistry letters.

[21]  R. Zhuo,et al.  Functional polymer/inorganic hybrid nanoparticles for macrophage targeting delivery of oligodeoxynucleotides in cancer immunotherapy , 2017 .

[22]  Ying Li,et al.  CRISPR-Cas9 delivery to hard-to-transfect cells via membrane deformation , 2015, Science Advances.

[23]  Hao Zhu,et al.  Non-Viral CRISPR/Cas Gene Editing In Vitro and In Vivo Enabled by Synthetic Nanoparticle Co-Delivery of Cas9 mRNA and sgRNA. , 2017, Angewandte Chemie.

[24]  T. Gajewski,et al.  Melanoma-intrinsic β-catenin signalling prevents anti-tumour immunity , 2015, Nature.

[25]  Wei Wang,et al.  NOR1 Suppresses Cancer Stem‐Like Cells Properties of Tumor Cells via the Inhibition of the AKT‐GSK‐3β‐Wnt/β‐catenin‐ALDH1A1 Signal Circuit , 2017, Journal of cellular physiology.

[26]  Hans Clevers,et al.  Genome-wide CRISPR screens reveal a Wnt–FZD5 signaling circuit as a druggable vulnerability of RNF43-mutant pancreatic tumors , 2016, Nature Medicine.

[27]  Soyoung Lee,et al.  Senescence-associated reprogramming promotes cancer stemness , 2017, Nature.

[28]  S. Ramakrishna,et al.  RGD/TAT-functionalized chitosan-graft-PEI-PEG gene nanovector for sustained delivery of NT-3 for potential application in neural regeneration. , 2018, Acta biomaterialia.

[29]  Haijun Shen,et al.  Tumor-specific delivery of doxorubicin through conjugation of pH-responsive peptide for overcoming drug resistance in cancer. , 2017, International journal of pharmaceutics.

[30]  Xiaoying Li,et al.  Knockout of CTNNB1 by CRISPR-Cas9 technology inhibits cell proliferation through the Wnt/β-catenin signaling pathway , 2018, Biotechnology Letters.

[31]  Peng Wang,et al.  Genome Editing for Cancer Therapy: Delivery of Cas9 Protein/sgRNA Plasmid via a Gold Nanocluster/Lipid Core–Shell Nanocarrier , 2017, Advanced science.

[32]  T. Grossmann,et al.  Direct targeting of β-catenin: Inhibition of protein-protein interactions for the inactivation of Wnt signaling. , 2013, Bioorganic & medicinal chemistry.

[33]  Hans Clevers,et al.  Wnt/β-Catenin Signaling in Development and Disease , 2006, Cell.

[34]  Xiaoyuan Chen,et al.  Non-viral delivery systems for CRISPR/Cas9-based genome editing: Challenges and opportunities. , 2018, Biomaterials.

[35]  Francisco J. Sánchez-Rivera,et al.  Applications of the CRISPR–Cas9 system in cancer biology , 2015, Nature Reviews Cancer.

[36]  Yoosoo Yang,et al.  Cancer‐derived exosomes as a delivery platform of CRISPR/Cas9 confer cancer cell tropism‐dependent targeting , 2017, Journal of controlled release : official journal of the Controlled Release Society.

[37]  Helmut Blum,et al.  Comprehensive analysis of β-catenin target genes in colorectal carcinoma cell lines with deregulated Wnt/β-catenin signaling , 2014, BMC Genomics.

[38]  Dian Yang,et al.  Pancreatic cancer modeling using retrograde viral vector delivery and in vivo CRISPR/Cas9-mediated somatic genome editing , 2015, Genes & development.

[39]  Hao Wang,et al.  Acquisition of epithelial-mesenchymal transition phenotype and cancer stem cell-like properties in cisplatin-resistant lung cancer cells through AKT/β-catenin/Snail signaling pathway. , 2014, European journal of pharmacology.

[40]  Yi-Wei Lee,et al.  Direct Cytosolic Delivery of CRISPR/Cas9-Ribonucleoprotein for Efficient Gene Editing. , 2017, ACS nano.

[41]  Wenjuan Ma,et al.  Aptamer-Modified Tetrahedral DNA Nanostructure for Tumor-Targeted Drug Delivery. , 2017, ACS applied materials & interfaces.

[42]  R. Zhuo,et al.  A Dual-Targeting Delivery System for Effective Genome Editing and In Situ Detecting Related Protein Expression in Edited Cells. , 2018, Biomacromolecules.

[43]  J. Doudna,et al.  CRISPR-Cas9 Structures and Mechanisms. , 2017, Annual review of biophysics.